Major test of first possible Lyme vaccine in 20 years begins
DUNCANSVILLE, Pa. (AP) — Researchers are seeking thousands of volunteers in the U.S. and Europe to test the first potential vaccine against Lyme disease in 20 years — in hopes of better fighting the tick-borne threat.
Lyme is a growing problem, with cases rising and warming weather helping ticks expand their habitat. While a vaccine for dogs has long been available, the only Lyme vaccine for humans was pulled off the U.S. market in 2002 from lack of demand, leaving people to rely on bug spray and tick checks.
Now Pfizer and French biotech Valneva are aiming to avoid previous pitfalls in developing a new vaccine to protect both adults and kids as young as 5 from the most common Lyme strains on two continents.
(See link for article)
Here we go again…..
- True to form, the only time ‘the powers that be’ bring up the fact Lyme/MSIDS is a growing problem is when there’s a vaccine in the pipeline.
- This “vaccine” targets OspA, the same protein in Lymerix that caused Lyme-like symptoms in many that was supposedly pulled due to “lack of demand.”
- The 36 hours for transmission is foolishly regurgitated as transmission can and often occurs much quicker, raising the question of whether or not there is even enough time for antibodies to do their supposed magic.
- Please notice that Pfizer and Valneva are behind this.
- French pharmaceutical company Valneva joined up with Pfizer (a company which has been fined over 3.5 billion for safety violations, false medical claims, corruption, bribery and has demanded countries put up sovereign assets, bank reserves, military bases and embassy buildings as collateral for expected lawsuits from COVID shots. This article outlines the fraud and corruption and questions how Pfizer managed to rebrand itself as savior of humanity (one could ask the same question about Bill Gates). If you still trust these companies I have land in Siberia I’d like to sell you.
- They aim to recruit 6,000 people, including kids as young as five, from endemic areas. Those who enroll will get three shots of either the vaccine or a placebo. It remains to be seen if it is truly a placebo – which should be an inert substance, or another vaccine, which they often do in trials to muddy the waters and make it impossible to truly determine safety. A year later they will get a booster.
- They consider this a seasonal vaccine and people will need to continue getting them.
- They state Lymerix drew “unsubstantiated reports of joint-related side effects.” I talk to these “unsubstantiated” patients regularly who are still suffering from the effects of Lymerix. Trust me when I say the damage is real, but don’t take my word for it, read about examples here and here. Hopefully by now it’s become clear that those who suffer vaccine damage are gaslit just like Lyme/MSIDS patients.
- The dirty little secret is LYMErix was given “permissive” recommendation by the CDC (the injection was only advised for those ‘at risk’, not the whole population). This designation allowed those suffering with adverse reactions to sue the manufacturer, which they did. I assure you, no such designation will be given this new jab and you will be SOL if you are injured from it.
- While this vaccine targets 6 Lyme strains, there are other strains out there, and this doesn’t touch coinfections which are often a part of the picture. Please note the continued singular attention to Lyme with no regard to other infections ticks carry. This one-microbe, one treatment, one vaccine paradigm is completely wrong but drives nearly all mainstream research.
- The article mentions the University of Massachusetts work on a “vaccine alternative” – shots of pre-made Lyme-fighting antibodies.
- Dr. Mark Klempner’s lucrative jab – Lyme PrEP, is now in Phase 1 trials. Please know the backstory on Klempner. He claims this new shot isn’t a “vaccine;” however, according to this, OspA is still in it, and this study states a wide range of neurological complications have been reported to VAERS after vaccination with OspA including cerebral ischemia, transient ischemic attacks, demyelinating events, optic neuritis, transverse myelitis and non-specific demyelination.
- Here’s what Dr. Stricker has to say:
OspA: Another Lyme OspA Vaccine Whitewash
“The meta-analysis by Zhao and colleagues comes to the conclusion that “the OspA vaccine against Lyme disease is safe and its immunogenicity and efficacy have been verified.” The authors arrive at this sunny conclusion by excluding 99.6% of published articles that demonstrate potential problems with the OspA vaccine. Furthermore, the authors ignore peer-reviewed studies, FDA regulatory meetings and legal proceedings that point to major problems with OspA vaccine safety (1-3). This whitewash bodes ill for future Lyme vaccine candidates because it fosters disregard for vaccine safety among Lyme vaccine manufacturers and mistrust among potential Lyme vaccinees.” ~ Dr. Stricker
- The article also mentions Yale’s work designing a vaccine that recognizes tick saliva — which in animal testing sparked a skin reaction that made it harder for ticks to hang on and feed.
- John Aucott is “cloning a bunch of proteins in tick saliva” to replicate tick resistance. He’s also an adviser to Tarsus Pharmaceuticals, a biopharmaceutical company which is authorized by the F.D.A. to develop an oral preventative in humans using lotilaner, the active ingredient in Credelio, a veterinary medication prescribed for dogs and cats to prevent fleas and ticks which is targeted to the parasite’s nervous system but supposedly doesn’t have any effect on mammals.
- This is where the money is – vaccines and seasonal treatments people will purchase time and again. Notice that nothing is ever said about an accurate test and effective treatments for suffering patients. Many, including yours truly believe Lyme was pigeonholed by the two principal investigators of the previous Lyme vaccines to fit a simplistic one pathogen paradigm for vaccine development. This is why they continue to deny chronic/persistent infection despite research to the contrary.
And speaking of money:
- The FDA in July 2017 issued Valneva a fast-track designation that specifically allows for expedited review of “drugs to treat serious conditions and fill an unmet medical need.”
- Valneva sold the rights to VLA15 to Pfizer for an upfront cost of $130 million in 2020, at which time the two companies announced a collaboration for the continued development and commercialization of the vaccine.
- Under the terms of the two companies’ agreement, the first dose in the Phase 2 study triggered an additional $10 million payment from Pfizer to Valneva.
- According to Fierce Biotech, a successful Phase 3 trial “could give Pfizer a clear run at a growing opportunity” and “offers Pfizer the chance to add a growth driver to its mammoth vaccine unit,” as the number of reported Lyme disease cases in the U.S. has increased threefold since the late 1990s. Source
- Mark Crispin Miller, a professor of media studies at New York University who has experienced the symptoms of Lyme disease, drew comparisons between the experimental Lyme disease vaccine and the COVID-19 vaccines.
“No doubt the CDC/FDA will bless this Lyme vaccine, regardless of its risks, just as they’ve pushed the COVID ‘vaccines’ for the last two years.
“And their support for this new vaccine is especially perverse, since the CDC et al. have long denied that ‘chronic Lyme’ exists, because its proper treatment would cost more than the insurance carriers want to pay.”
“As one who has been battling Lyme for more than 10 years, and at enormous cost, I see no reason to put any trust at all in those authorities, whose long denial of the reality of this condition has done me, and countless others, grievous harm.” ~ Mark Crispin Miller
I couldn’t agree more.
And I’m with Lyme Advocate Carl Tuttle: No Lyme Vaccine Until persistent infection is acknowledged and fully addressed.